communityacquir
pneumonia
cap
lead
caus
morbid
mortal
age
group
worldwid
african
contin
carri
substanti
burden
around
estim
million
episod
lower
respiratori
tract
infect
lrti
year
bacteria
exampl
streptococcu
pneumonia
princip
caus
agent
adult
pneumonia
howev
avail
sensit
molecular
test
result
increas
recognit
virus
major
contributor
moreov
emerg
avian
influenza
viru
pandem
influenza
viru
along
acceler
discoveri
novel
respiratori
virus
eg
human
metapneumoviru
hmpv
bocaviru
coronavirus
middl
east
respiratori
syndrom
mer
backdrop
grow
popul
immunocompromis
individu
catalys
research
attent
sever
viral
respiratori
infect
adult
avail
data
contribut
virus
adult
cap
come
mainli
studi
develop
set
viral
caus
pneumonia
african
adult
less
well
characteris
larg
due
lack
access
appropri
diagnost
epidemiolog
aetiolog
agent
season
age
distribut
patient
like
differ
substanti
develop
set
myriad
reason
firstli
respiratori
virus
typic
follow
season
pattern
contrast
distinct
winter
epidem
seen
temper
region
avail
influenza
data
indic
year
round
transmiss
african
region
secondli
high
preval
human
immunodefici
viru
hiv
infect
comorbid
eg
tuberculosi
tb
like
impact
epidemiolog
microbi
aetiolog
adult
viral
respiratori
present
sever
pneumonia
aetiolog
studi
africa
describ
preponder
younger
adult
age
year
addit
lrti
herp
virus
cytomegaloviru
cmv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
common
adult
western
set
children
subsaharan
africa
advanc
immunosuppress
moreov
immunocompromis
patient
may
sever
present
emerg
data
south
africa
describ
higher
risk
death
hivinfect
adult
influenza
infect
lastli
mani
develop
set
recommend
target
univers
season
influenza
vaccin
african
countri
nation
influenza
vaccin
programm
paper
review
current
knowledg
epidemiolog
aetiolog
viral
pneumonia
adult
older
children
subsaharan
africa
evalu
avail
option
diagnosi
prevent
manag
viral
respiratori
pathogen
resourcepoor
set
absenc
standardis
case
definit
longstand
problem
pneumonia
aetiolog
studi
studi
undertaken
develop
set
focus
radiologicallyconfirm
pneumonia
ie
presenc
new
infiltr
chest
radiograph
xray
clinic
symptom
suggest
lrti
given
inconsist
avail
chest
radiograph
african
health
set
broader
definit
pneumonia
use
includ
clinic
evid
lrti
without
confirm
chest
radiograph
chang
literatur
search
origin
research
articl
use
pubm
databas
incept
may
conduct
follow
pubm
search
strategi
use
acut
respiratori
infect
field
acut
lower
respiratori
tract
infect
field
sever
acut
respiratori
infect
field
pneumonia
field
pneumonia
mesh
term
africa
mesh
term
africa
field
follow
inclus
criteria
use
studi
popul
patient
age
year
age
ii
studi
popul
patient
radiologicallyconfirm
pneumonia
clinic
lrti
iii
studi
popul
patient
hospitalis
iv
studi
languag
sinc
purpos
review
describ
viral
caus
pathogen
african
adult
older
children
present
pneumonia
studi
examin
influenza
bacteri
pathogen
exclud
figur
result
expand
armamentarium
diagnost
test
viralvir
viralbacteri
coinfect
increasingli
identifi
sever
studi
wellresourc
set
found
sever
diseas
poorer
outcom
patient
polymicrobi
infect
howev
clinic
interpret
mix
infect
straightforward
sinc
detect
multipl
pathogen
could
reflect
three
possibl
scenario
detect
organ
contribut
pathogenesi
ii
detect
organ
innoc
bystand
iii
one
organ
predispos
factor
eg
damag
respiratori
epithelium
caus
pneumonia
second
organ
influenza
viru
pneumonia
studi
coinfect
combin
synergist
interact
well
describ
african
set
pneumococc
conjug
vaccin
pcv
shown
prevent
viral
pneumonia
south
african
children
provid
epidemiolog
evid
import
pneumococc
coinfect
viral
pneumonia
recent
hospitalbas
surveil
studi
south
africa
describ
elev
blood
pneumococc
load
marker
invas
pneumococc
pneumonia
patient
influenza
viru
coinfect
one
includ
african
studi
describ
mix
infect
scott
et
al
report
bacteri
pneumonia
case
influenza
viral
coinfect
rhinoviru
n
coronavirus
rsv
piv
type
bacteriafungu
includ
staphylocccu
aureu
klebsiella
pneumonia
p
jiroveci
tuberculosi
demonstr
case
malawian
hdu
cohort
recent
ari
surveil
studi
kenya
demonstr
mix
viral
bacteri
infect
patient
coinfect
common
hivposit
hivneg
patient
influenza
viru
less
like
coinfect
virus
compar
viral
pathogen
pretoriu
et
al
report
viral
coinfect
hospitalis
pneumonia
patient
includ
children
year
unabl
correl
coinfect
clinic
outcom
due
low
number
specif
coinfect
combin
among
coinfect
patient
kenyan
south
african
studi
adenoviru
rhinoviru
rsv
frequent
detect
virus
feikin
et
al
found
similar
preval
rhinoviru
adenoviru
case
control
impli
identif
ari
case
may
clinic
signific
nonetheless
contribut
commonli
identifi
virus
diseas
sever
often
unclear
avail
literatur
role
rhinoviru
pneumonia
contenti
one
hand
asymptomat
carriag
well
describ
immunocompet
immunocompromis
patient
convers
viral
shed
beyond
week
acut
ill
rare
suggest
associ
clinic
diseas
furthermor
rhinoviru
associ
hospitalis
lrti
thai
adult
also
suspect
caus
organ
sever
outbreak
sever
respiratori
diseas
nurs
home
unit
state
contrast
asymptomat
carriag
adenoviru
rsv
uncommon
henc
presenc
usual
pathogen
adenoviru
implic
caus
pneumonia
south
african
chines
adult
although
neither
studi
control
group
given
wide
variat
time
period
studi
popul
pneumonia
definit
clinic
specimen
diagnost
method
number
pathogen
test
difficult
make
firm
conclus
hand
studi
avail
beyond
viral
pathogen
preval
older
children
adult
subsaharan
africa
present
sever
ari
mix
infect
common
except
feikin
et
al
lack
control
group
major
limit
background
preval
asymptomat
viral
infect
undefin
see
section
role
healthi
control
convent
diagnost
method
viral
cultur
immunofluoresc
microscopi
respiratori
specimen
serolog
test
acut
convalesc
serum
sampl
limit
clinic
applic
due
lengthi
process
time
poor
sensit
nucleic
acid
amplif
test
nat
pcrbase
method
greatli
enhanc
detect
respiratori
viral
pathogen
demonstr
superior
sensit
compar
convent
method
abl
detect
virus
difficult
cultur
eg
hmpv
coronavirus
rhinoviru
rapidli
characteris
new
viral
pathogen
yield
result
clinic
relev
time
frame
moreov
multiplex
platform
enabl
simultan
detect
larg
number
viral
pathogen
singl
specimen
thu
facilit
diagnost
effici
costeffect
studi
wellresourc
set
demonstr
higher
microbi
yield
convent
diagnost
techniqu
augment
nat
form
backbon
respiratori
viral
test
well
resourc
surveil
site
lowincom
set
lower
respiratori
tract
sampl
eg
induc
sputum
bronchoalveolar
lavag
transthorac
needl
aspir
provid
sensit
specimen
determin
like
caus
pneumonia
sinc
taken
site
infect
howev
difficult
obtain
unfeas
african
set
viral
diagnosi
therefor
mostli
reli
upper
respiratori
specimen
high
sensit
molecular
test
complic
interpret
posit
result
virus
identifi
nasopharyng
specimen
underli
caus
lrti
may
also
repres
contamin
colonis
postinfecti
shed
predispos
agent
subsequ
bacteri
superinfect
thu
attribut
causal
everi
posit
pcr
result
may
overestim
contribut
respiratori
virus
particularli
diagnost
test
pathogen
blood
cultur
compar
low
sensit
molecular
result
interpret
context
patient
clinic
present
known
epidemiolog
detect
viral
pathogen
addit
viral
load
quantif
ascertain
background
preval
asymptomat
nasopharyng
viral
infect
control
group
could
clarifi
pathogen
role
detect
virus
studi
design
analog
perch
studi
wherebi
multipl
upper
lower
respiratori
specimen
obtain
pneumonia
case
commun
control
allow
strength
associ
posit
result
pneumonia
establish
addit
comparison
concord
microbi
result
upper
lower
respiratori
specimen
patient
past
decad
emerg
highli
pathogen
avian
influenza
viru
pandem
influenza
viru
highlight
need
strengthen
capac
ari
surveil
subsaharan
africa
financi
technic
support
nation
intern
institut
world
health
organis
center
diseas
control
prevent
cdc
institut
pasteur
nation
institut
communic
diseas
south
africa
grow
number
countri
region
acquir
pcr
diagnost
capabl
least
african
countri
contribut
specimen
influenza
surveil
nevertheless
oper
molecular
diagnosi
laboratori
resourcepoor
set
associ
major
challeng
requir
reliabl
power
sourc
access
reagent
equip
train
technician
skill
mainten
addit
robust
sampl
transfer
storag
system
stringent
qualiti
control
repres
signific
barrier
widespread
implement
pcr
test
africa
forese
futur
pcr
diagnost
like
confin
research
set
institutionallysupport
surveil
programm
howev
demonstr
substanti
burden
respiratori
virus
ari
may
gather
momentum
global
health
partner
expand
respiratori
viral
diagnost
capabl
subsaharan
countri
convinc
govern
individu
countri
invest
infrastructur
support
pcr
diagnosi
step
toward
sustain
antivir
respiratori
virus
prohibit
expens
larg
unavail
subsaharan
africa
despit
like
preval
cmv
pneumon
publish
report
ganciclovir
use
adult
cmv
diseas
contin
except
aciclovir
treatment
hsv
vzv
antiinfluenza
agent
name
neuraminidas
inhibitor
ni
oseltamivir
zanamavir
inhibitor
amantadin
rimantadin
antivir
avail
small
number
african
set
moreov
due
widespread
resist
season
influenza
viru
pandem
influenza
viru
recent
year
inhibitor
longer
recommend
treatment
prophylaxi
influenza
viru
ni
shown
effect
prevent
influenza
healthi
adult
children
develop
set
recent
cochran
review
oseltamivir
associ
shorten
ill
durat
day
due
lack
diagnost
definit
unclear
whether
ni
reduc
risk
influenza
complic
pneumonia
though
effect
rate
hospitalis
data
impact
ni
hospitalis
immunosuppress
patient
influenza
pneumonia
scarc
current
evid
larg
deriv
retrospect
studi
suggest
oseltamivir
acceler
viral
clearanc
reduc
length
hospit
stay
well
lower
mortal
patient
hospitalis
influenza
specif
hivinfect
individu
sever
studi
suggest
oseltamivir
reduc
sever
ill
prospect
evalu
efficaci
ni
hivinfect
individu
african
set
undertaken
ni
effect
administ
within
hour
symptom
onset
lack
viral
test
realtim
broad
differenti
diagnosi
acut
respiratori
present
high
hiv
preval
set
addit
high
cost
lack
avail
barrier
widespread
effect
use
ni
region
present
shortag
therapeut
option
prevent
control
viral
pneumonia
focus
infect
control
vaccin
core
infect
control
measur
cohort
isol
impract
mani
resourcepoor
set
howev
physic
intervent
handwash
use
mask
glove
apron
may
feasibl
implement
minimis
risk
nosocomi
spread
vaccin
option
limit
prevent
respiratori
viral
infect
approv
vaccin
season
influenza
wellresourc
set
annual
influenza
vaccin
trival
quadrival
inactiv
vaccin
tivqiv
intranas
live
attenu
vaccin
lav
establish
role
prevent
influenza
infect
complic
lav
contraind
immunosuppress
pregnant
patient
thu
unsuit
widespread
use
subsaharan
africa
hiv
preval
high
studi
evalu
efficaci
effect
tiv
africa
south
africa
ageadjust
vaccin
effect
tiv
estim
surveil
programm
patient
influenzalik
ill
ili
rang
ci
though
low
vaccin
coverag
approxim
among
ili
case
may
reduc
power
estim
vaccin
effect
randomis
doubl
blind
placebocontrol
trial
tiv
hivinfect
adult
demonstr
vaccin
efficaci
ci
compar
develop
set
howev
exclud
patient
underli
comorbid
advanc
immunosuppress
antiretrovir
therapi
evalu
tiv
qiv
efficaci
highrisk
group
requir
recent
cdc
survey
report
avail
season
influenza
vaccin
african
countri
howev
subsaharan
african
countri
ivoir
mauritiu
report
nation
public
polici
influenza
vaccin
even
annual
season
influenza
vaccin
becam
nation
polici
implement
logist
challeng
current
indigen
vaccin
product
region
addit
vaccin
donat
initi
provid
pandem
influenza
viru
vaccin
also
highlight
problem
vaccin
procur
distribut
uptak
region
number
vaccin
import
viral
pathogen
rsv
piv
type
develop
furthermor
given
protect
effect
pneumococc
vaccin
viral
pneumonia
children
current
pcv
rollout
children
number
african
countri
may
result
indirect
benefit
adult
viral
pneumonia
increas
deploy
sensit
molecular
diagnost
assay
improv
abil
characteris
contribut
virus
adult
pneumonia
virus
commonli
identifi
cap
western
settingnam
rhinoviru
influenza
viru
rsv
piv
preval
adult
older
children
present
hospitalis
pneumonia
subsaharan
africa
novel
virus
hmpv
human
bocaviru
increasingli
identifi
review
highlight
scarciti
literatur
viral
aetiolog
adult
cap
especi
atrisk
group
hivinfect
individu
though
data
begin
emerg
sari
surveil
prospect
observ
studi
vaccin
treatment
option
viral
respiratori
pathogen
remain
limit
reach
subsaharan
africa
evid
use
set
lack
nonetheless
ongo
epidemiolog
surveil
import
evalu
tempor
variat
circul
virus
anticip
futur
outbreak
pandem
better
characteris
burden
spectrum
virus
contribut
adult
cap
region
also
enabl
inform
interpret
posit
molecular
result
aid
decis
import
pathogen
includ
respiratori
diseas
surveil
programm
well
pathogen
virus
target
vaccin
antivir
develop
furthermor
establish
substanti
burden
virusassoci
sever
respiratori
infect
particular
influenza
may
persuad
local
polici
maker
consid
target
immunis
programm
annual
influenza
vaccin
atrisk
adult
pcv
children
could
potenti
prevent
substanti
proport
viral
pneumonia
adult
